Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how certain blood cells called megakaryocytes, which help produce platelets that stop bleeding, behave in people having heart surgery called coronary artery bypass grafting. The study aims to better understand these cells by looking at them in the bone marrow and in the bloodstream before, during, and after surgery using a special lab technique called flow cytometry. This could help doctors learn more about how the body responds to surgery and heals.

Adults over 18 who are scheduled for this type of planned heart surgery and have current health coverage may be eligible to join, as long as they can understand the study and agree to take part. People who have other serious health conditions, recent cancer treatment, or who are having emergency surgery would not be included. Participants will have blood and bone marrow samples taken to study the megakaryocytes, which means extra tests beyond routine care. This study is not yet enrolling patients but aims to provide helpful information about how the body’s blood cell production changes during heart surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Age over 18
• • Indication for programmed cardiac surgery, specifically coronary artery bypass grafting with sternotomy
• • Up to date social security coverage
• • Patients able to understand the purpose and constraints of the research project
• Exclusion Criteria:
• • Refusal to participate in the study,
• • Pregnant and/or breastfeeding women (clinical interview),
• • Unscheduled cardiac surgery, Acquired hematologic disorders (acute leukemia, lymphomas, myelodysplastic syndromes, and myeloproliferative syndromes)
• • Treatment with thrombopoietin receptor agonists
• • Treatment with anti-inflammatory (included corticoids) or/and immunosuppressors
• • Hematopoietic stem cell transplantation or organ transplantation
• • Active cancer with or without treatment (in remission, ongoing or treated within the last 6 months),
• • Palliative care patients
• • Any other type of cardiac surgery and previous sternotomy,
• • History of external thoracic radiotherapy,
• • Patient under legal protection (curatorship, guardianship or safeguard of justice)
• • Patients with ongoing clinical trial requiring collection of additional blood or bone marrow samples